Nusano
Are you looking for a reliable medical radioisotope supplier? Nusano is a high-quality radioisotopes production platform company headquartered in the US. Contact us!
Company - Nusano
Nusano is a radioisotope production company making medical radioisotopes that can be targeted to cancer cells with precision –enabling new ways to detect and eradicate cancer and other deadly diseases.
Nusano Opens Radiochemistry Laboratory to Advance Isotope ...
Mar 11, 2024 · Nusano’s technologies will supply the fight against cancer and support diagnostic and therapeutic radiopharmaceutical development. The company’s state-of-the-art production facility opens Q1 2025 in West Valley City, Utah.
Collaboration to Enable Next Generation Radiotherapeutics
May 15, 2023 · Nusano’s technologies will supply the fight against cancer and support diagnostic and therapeutic radiopharmaceutical development. The company’s state-of-the-art production facility opens Q1 2025 in West Valley City, Utah.
Nusano Adds to Executive Leadership Team in Advance of 2025 ...
VALENCIA, Calif. – Oct. 3, 2024 – Nusano, Inc., a physics company transforming the production of medical radioisotopes, today announced the addition of two executives to support its business commercialization and the availability of non-carrier-added …
CHRIS LOWE - Nusano
Chris Lowe is an accomplished business leader with more than 30 years’ experience, the past 20 of which in C-suite and executive-level roles in healthcare and finance. He brings extensive strategic and operational expertise to Nusano, including licensing, financing and acquisitions.
Nusano and Starget Pharma Announce Supply Agreement to …
Oct 17, 2024 · Driven by the company’s proprietary ion source, the Nusano production platform will generate radioisotopes in volumes and varieties exceeding other production methods. Nusano’s breakthrough technologies are poised to help supply the fight against cancer and enable innovation across multiple industries. For more, please visit www.nusano.com.
Technology - Nusano
The Nusano platform is capable of generating up to 12 different isotopes simultaneously – a giant leap forward – enabling commercial-scale production of the active pharmaceutical ingredients needed for next-generation cancer diagnostics and therapeutics.
Nusano Announces Series C Financing of Over $115M to …
Oct 1, 2024 · Nusano announced a Series C financing round with funding commitments of over $115 million in total proceeds. The financing will support the company’s initial product launches of non-carrier-added lutetium-177 (n.c.a. Lu-177) and actinium-225 (Ac-225).
Products - Nusano
Nusano’s production platform enables the creation of rare and hard-to-produce medIcial radioisotopes in quantities needed for commercial-stage diagnostics and therapeutics. Product capabilities include, but are not limited to, the isotopes listed alphabetically below.